[{"id":"e2f74266-764b-4a6c-ba8a-c37768277e10","acronym":"","url":"https://clinicaltrials.gov/study/NCT05168748","created_at":"2021-12-23T16:53:45.538Z","updated_at":"2024-07-02T16:35:58.778Z","phase":"Phase 1","brief_title":"CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT05168748","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CD22","pipe":" | ","alterations":" CD19 expression • CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression • CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IMJ995"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/24/2023","start_date":" 01/24/2023","primary_txt":" Primary completion: 08/13/2026","primary_completion_date":" 08/13/2026","study_txt":" Completion: 08/13/2026","study_completion_date":" 08/13/2026","last_update_posted":"2022-12-21"}]